Biotechnology company focused on the discovery and development of innovative medicines.
Galapagos NV, headquartered in Mechelen, Belgium, and established in 1999, is an integrated biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines addressing high unmet medical needs. Among its leading pipeline products is filgotinib, a JAK1 inhibitor undergoing various phases of clinical trials for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel Crohn's disease, fistulizing Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and uveitis.
The company's diverse pipeline also includes GLPG1972, which has completed a Phase 2b trial for osteoarthritis treatment, and several Toledo molecules like GLPG3970, GLPG4399, and GLPG4876 targeting inflammation. Additionally, Galapagos is developing GLPG4716 and Ziritaxestat for idiopathic pulmonary fibrosis. In the realm of genetic disorders, GLPG2737, a cystic fibrosis transmembrane conductance regulator, is in Phase 2 trials for autosomal dominant polycystic kidney disease, while GLPG0555, another JAK1 inhibitor, is in Phase 1b for osteoarthritis.
Galapagos NV collaborates with prominent pharmaceutical companies, including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG, to advance its research and development efforts. Through these strategic partnerships and its robust pipeline, Galapagos is committed to bringing groundbreaking therapies to market, addressing significant gaps in treatment, and improving patient outcomes.